Drug Profile
Autologous mesenchymal stem cell therapy - EHL Bio
Alternative Names: ADSTEM injectionLatest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator EHL Bio
- Class Mesenchymal stem cell therapies; Stem cell therapies
- Mechanism of Action Cell replacements; Stem cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Atopic dermatitis
Most Recent Events
- 28 Aug 2019 No recent reports of development identified for phase-I development in Atopic-dermatitis in South Korea (IV, Injection)
- 01 Dec 2017 EHL Bio completes a phase I trial in Atopic dermatitis in South Korea (IV) (NCT02888704)
- 01 Jul 2016 Phase-I clinical trials in Atopic dermatitis in South Korea (IV) (NCT02888704)